Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00048165 |
The purpose of this study is to determine whether the combination of Zenapax, CellCept, Cyclosporine and Corticosteroids are effective in patients receiving heart transplants.
Condition | Intervention | Phase |
---|---|---|
Transplantation |
Drug: ZENAPAX |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NR15880 |
Study First Received: | October 24, 2002 |
Last Updated: | December 15, 2005 |
ClinicalTrials.gov Identifier: | NCT00048165 |
Health Authority: | United States: Food and Drug Administration |
Cyclosporine Daclizumab Mycophenolate mofetil Cyclosporins |
Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |